Precision LBx Summit 2017

Touted as the "holy grail" of diagnostics, liquid biopsy promises real time longitudinal patient monitoring and cost effective diagnostic screening. However, still in its infancy, the field is grappling with proving and advancing the clinical utility of liquid biopsies. Coinciding with the first FDA approval of a clinical liquid biopsy test, the inaugural Precision LBx Summit will help large biopharma, research laboratories and diagnostic organizations capitalize on this potential. For more information visit: www.lbx-summit.com